A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Phase 1

Completed

• Conditions: Small Cell Lung Cancer; Small Cell Lung Carcinoma
• Interventions: Drug: ABT-263

• Registration Number: NCT00445198
• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary

The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-03-06
• Study First Submitted QC: 2007-03-06
• Study First Posted: 2007-03-08
• Study Start: 2007-04
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Disposition First Submitted: 2011-12-22
• Disposition First Submitted QC: 2011-12-22
• Disposition First Posted: 2011-12-26
• Status Verified: 2013-01
• Last Update Submitted: 2018-06-01
• Last Update Posted: 2018-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

• The subject must be >=18 years of age.(Phase 1 & 2a)

• Histologically and/or cytologically documented diagnosis of small cell lung cancer (North America & UK) or other non-hematological malignancy (North America only).(Phase 1 only)

• Histologically and/or cytologically documented diagnosis of SCLC.(Phase 2a)

• At least one prior chemotherapy treatment regimen(s) and their disease is refractory or experienced progressive disease following the treatment.(Phase 1)

• Extensive-stage SCLC & is chemotherapy naïve(US only) has experienced progressive disease following at least one chemotherapy regimen or their disease is refractory.(Phase 2a)

• Brain metastases with clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function & no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.

• ECOG performance score <= 2(Ph 1) <=1(Phase 2a)

• Must be receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants 21 days prior to 1st dose of study drug.

• Adequate bone marrow, renal & hepatic function per local lab reference range at Screening as follows:

  • Bone marrow: Absolute Neutrophil count (ANC)>=1000/µL
  • Platelets>= 100,000/mm3
  • Hemoglobin>=9.0g/dL
  • Renal function: Serum creatinine<= 2.0mg/dL or calculated creatinine clearance>=50mL/min
  • Hepatic function&enzymes: AST and ALT<=3.0 x the upper normal limit(ULN) of institution's normal range
  • Bilirubin<=1.5xULN. If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
  • Coagulation: aPTT and PT<=1.2 x the upper limit of normal

• Should have archived diagnostic tissue available for assessment of Bcl-2 family protein expression.(Phase 2a)

• All female subjects not surgically sterile or postmenopausal(for at least 1 year)and non-vasectomized male subject must practice at least one method of birth control.

Exclusion Criteria

• Underlying or predisposing condition of bleeding or currently exhibits signs of bleeding.

• Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.

• Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.

• The subject has active immune thrombocytopenic purpura (ITP),active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).

• Currently receiving or requires anticoagulation therapy or any drug or herbal supplements that affect platelet function, with exception of low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter.

• Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti estrogen analogs, agonists required to suppress serum testosterone levels), or any investigational therapy within 14 days prior to the first dose of study drug, or has not recovered to less than a grade 2 adverse effect(s) of the previous therapy.

• Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the first dose of study drug.

• Steroid therapy for anti-neoplastic intent within seven days prior to the first dose of study drug.

• Has consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.

• Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.

• Positive for HIV

• A history of other active malignancies within the past 3 years prior to screening, with the exception of:

  • Adequately treated in situ carcinoma of the cervix uteri
  • Basal or squamous cell carcinoma of the skin
  • Previous malignancy confined and surgically resected with curative intent

• Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

  • Active systemic fungal infection
  • Diagnosis of fever and neutropenia within 1 week prior to study drug administration.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Phase 1 and Phase 2a	ABT-263	-

Primary Outcome Measures

Name	Time	Method
Safety assessment	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
Dose limiting toxicity determination	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
Maximum tolerated dose determination	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
Pharmacokinetic profile evaluation	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing

Secondary Outcome Measures

Name	Time	Method
Preliminary efficacy assessment	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
Extended safety assessment at the recommended Phase 2 dose	Repeating sequence of 14 days on therapy and 7 days off or continuous dosing

Trial Locations

Locations (18)

Site Reference ID/Investigator# 13605; 🇺🇸 Peoria, Arizona, United States

Site Reference ID/Investigator# 4718; 🇺🇸 Sacramento, California, United States

Site Reference ID/Investigator# 11942; 🇺🇸 Los Angeles, California, United States

Site Reference ID/Investigator# 12343; 🇺🇸 Bethesda, Maryland, United States

Site Reference ID/Investigator# 2626; 🇺🇸 Boston, Massachusetts, United States

Site Reference ID/Investigator# 2625; 🇺🇸 Baltimore, Maryland, United States

Site Reference ID/Investigator# 5261; 🇺🇸 Phoenix, Arizona, United States

Site Reference ID/Investigator# 2623; 🇺🇸 Chicago, Illinois, United States

Site Reference ID/Investigator# 8324; 🇺🇸 Atlanta, Georgia, United States

Site Reference ID/Investigator# 3755; 🇺🇸 Aurora, Colorado, United States

Site Reference ID/Investigator# 11941; 🇺🇸 Boston, Massachusetts, United States

Site Reference ID/Investigator# 2624; 🇺🇸 Nashville, Tennessee, United States

Site Reference ID/Investigator# 4934; 🇺🇸 Charlotte, North Carolina, United States

Site Reference ID/Investigator# 7635; 🇨🇦 Ottawa, Canada

Site Reference ID/Investigator# 7493; 🇨🇦 Edmonton, Canada

Site Reference ID/Investigator# 6650; 🇺🇸 Tacoma, Washington, United States

Site Reference ID/Investigator# 18541; 🇬🇧 Leicester, United Kingdom

Site Reference ID/Investigator# 2622; 🇬🇧 Manchester, United Kingdom